JFrog Ltd. FROG 深 滬
等待開盤 02-05 09:30:00 美东时间
52.00
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 52.00
- 總市值 61.36亿
- 52周最高 70.4299
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 27.00
- 委 比 0.00%
- 總股本 1.18亿
- 歷史最高 95.20
- 量 比 0
- 振 幅 0.00%
- 歷史最低 16.356
- 每 手 1
- 風險率 10.18%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 泰瑞达、Lumentum、哈贝尔、Enphase能源、西部数据获多家机构上调目标价；PayPal 、恩智浦、墨式烧烤遭多家机构下调目标价
今日重点评级关注：韦德布什：维持Replimune Group"跑赢大市"评级，目标价从18美元升至19美元；巴克莱：维持CytomX Therapeutics"超配"评级，目标价从8美元升至10美元
今天 11:28
Cantor Fitzgerald Reiterates Overweight on JFrog, Maintains $80 Price Target
Cantor Fitzgerald analyst Jonathan Ruykhaver reiterates JFrog (NASDAQ:FROG) with a Overweight and maintains $80 price target.
今天 00:05
JFrog CTO Yoav Landman Reports Sale of Common Shares
JFrog CTO Yoav Landman Reports Sale of Common Shares Yoav Landman, Chief Technology Officer and Director of JFrog Ltd., has reported a disposal of common shares of JFrog Ltd. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT)
01-22 05:15
美股大行评级 | Medline获14家大行首予评级，最高目标价52美元；富国银行上调GOOGL目标价从268美元升至350美元
今日重点评级关注：HC Wainwright & Co.：维持Enlivex Therapeutics"买入"评级，目标价从7美元升至13美元；BTIG：维持Oruka Therapeutics"买入"评级，目标价从63美元升至73美元
01-13 10:18
Barclays Maintains Overweight on JFrog, Raises Price Target to $70
Barclays analyst Ryan Macwilliams maintains JFrog (NASDAQ:FROG) with a Overweight and raises the price target from $67 to $70.
01-13 04:03
美股大行评级 | 瑞银上调美光科技目标价从300美元升至400美元；Freedom上调百度目标价从120美元升至160美元
今日重点评级关注：Needham：维持Vaxcyte"买入"评级，目标价从90美元升至110美元；Citizens: 维持LGI Homes"跑赢大市"评级，目标价从85美元升至95美元
01-08 18:33
Oppenheimer’s best small and mid-cap ideas for 2026
Oppenheimer Research released a list of its best ideas for small-caps and mid-caps in the new year. Analysts said that, absent the traditional warning signs that have historically preceded market down...
01-07 00:59
美股大行评级 | 潜在涨幅36.7%！LMRI获多家大行首予超配评级； 瑞银下调甲骨文目标价从325美元至280美元
今日重点评级关注：HC Wainwright & Co.：维持Assertio Holdings"买入"评级，目标价从3美元升至35美元；HC Wainwright & Co.：维持万达生物制药"买入"评级，目标价从20美元升至22美元
01-06 17:52
Piper Sandler Maintains Neutral on JFrog, Raises Price Target to $70
Piper Sandler analyst Rob Owens maintains JFrog (NASDAQ:FROG) with a Neutral and raises the price target from $60 to $70.
01-06 00:47
Security Tech Check-In: Analyst Insights From 12 Companies Ahead Of The 'Quiet Period'
Needham analysts met with 12 companies before quiet period. Ratings and price targets by analyst Mike Cikos.
2025-12-19 03:38
